{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:07:30Z","timestamp":1791313650313,"version":"4.3.1"},"reference-count":24,"publisher":"The Journal of Rheumatology","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Abatacept (ABA) has recently been proposed as second-line treatment in patients with juvenile idiopathic arthritis (JIA)\u2013associated uveitis refractory to anti\u2013tumor necrosis factor-\u03b1 (anti-TNF) agents, but little is known about its efficacy as a first-line approach. The aim of the present study was to compare the safety and efficacy of ABA as a first-line biological agent (ABA-1) with that of ABA as a second-line treatment after 1 or more anti-TNF agents (ABA-2), in patients with severe JIA-related uveitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>In this multicenter study, we collected data on patients with severe JIA-related uveitis treated with ABA as a first-line or second-line biological agent. Changes in frequency of uveitis flares\/year and ocular complications before and after ABA treatment, clinical remission, and side effects were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Thirty-five patients with a mean age of 10.8 years were treated with ABA for a mean period of 19.6 months. In 4 patients, ABA administration was discontinued, owing to inefficacy on arthritis in 3 cases and allergic reaction in 1. Thirty-one patients, 14 in the ABA-1 group and 17 in the ABA-2 group, completed the 12-month followup period; of these, 17 (54.8%) had clinical remission. The mean frequency of uveitis flares decreased from 4.1 to 1.2 in the ABA-1 group (p = 0.002) and from 3.7 to 1.2 in the ABA-2 group (p = 0.004). Preexisting ocular complications improved or remained stable in all but 5 patients, all in the ABA-2 group. No significant difference was found between the efficacy of the 2 treatment modalities. ABA confirmed its good safety profile.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>ABA, used as first-line biological treatment or after 1 or more anti-TNF agents, induces a comparable improvement in severe refractory JIA-related uveitis.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.151389","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T02:04:02Z","timestamp":1473991442000},"page":"2068-2073","source":"Crossref","is-referenced-by-count":58,"title":["Comparable Efficacy of Abatacept Used as First-line or Second-line Biological Agent for Severe Juvenile Idiopathic Arthritis-related Uveitis"],"prefix":"10.3899","volume":"43","author":[{"given":"Carolina","family":"Birolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisabetta","family":"Zannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Arsenyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Cimaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Miserocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Dubko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal Job","family":"Deslandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Falcini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"La Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Denisova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Nikishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zulian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2016,9,15]]},"reference":[{"key":"2018112909362412000_43.11.2068.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2013.05.005"},{"key":"2018112909362412000_43.11.2068.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22918"},{"key":"2018112909362412000_43.11.2068.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058248"},{"key":"2018112909362412000_43.11.2068.4","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.137794"},{"key":"2018112909362412000_43.11.2068.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120583"},{"key":"2018112909362412000_43.11.2068.6","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20404"},{"key":"2018112909362412000_43.11.2068.7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22214"},{"key":"2018112909362412000_43.11.2068.8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1681\/ASN.V132559","article-title":"The role of novel T cell costimulatory pathways in autoimmunity and transplantation","volume":"13","author":"Yamada","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2018112909362412000_43.11.2068.9","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20115"},{"key":"2018112909362412000_43.11.2068.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"2018112909362412000_43.11.2068.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.01.014"},{"key":"2018112909362412000_43.11.2068.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken298"},{"key":"2018112909362412000_43.11.2068.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050524"},{"key":"2018112909362412000_43.11.2068.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60998-8"},{"key":"2018112909362412000_43.11.2068.15","first-page":"1897","article-title":"Abatacept for refractory juvenile idiopathic arthritis-associated uveitis - a case report","volume":"35","author":"Angeles-Han","year":"2008","journal-title":"J Rheumatol"},{"key":"2018112909362412000_43.11.2068.16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/acr.20359","article-title":"Abatacept for refractory juvenile idiopathic arthritis\u2013associated uveitis: two new cases. Comment on the article by Zulian et al","volume":"63","author":"Elhai","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2018112909362412000_43.11.2068.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-010-1523-6"},{"key":"2018112909362412000_43.11.2068.18","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2147\/OPTH.S23646","article-title":"Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"5","author":"Kotaniemi","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"2018112909362412000_43.11.2068.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-013-2275-x"},{"key":"2018112909362412000_43.11.2068.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140410"},{"key":"2018112909362412000_43.11.2068.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.27431"},{"key":"2018112909362412000_43.11.2068.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.085084"},{"key":"2018112909362412000_43.11.2068.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.23397"},{"key":"2018112909362412000_43.11.2068.24","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-11-16"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.151389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T16:01:44Z","timestamp":1657296104000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.151389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,15]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,1]]},"published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.3899\/jrheum.151389"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.151389","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,15]]}}}